Lymphocyte Level Profile Between Active and Inactive Systemic Lupus Erythematosus Patients Receiving Methylprednisolon Therapy

Authors

  • Rudi erwin Kurniawan Fakultas Kedokteran, Insititut Kesehatan medistra Lubuk Pakam

DOI:

https://doi.org/10.35451/pwmsfc33

Keywords:

Limfosit, Systemic Lupus Erythematosus (SLE, Methylprednisolon

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by chronic inflammation and excessive lymphocyte activation, requiring accurate monitoring of disease activity. This study aimed to analyze the differences in lymphocyte levels between active and inactive SLE patients receiving methylprednisolone therapy. The methodology involved measuring lymphocyte counts from patients’ venous blood samples, followed by classification based on the MEX-SLEDAI score as an indicator of disease activity. Data were then analyzed to determine significant differences between the two groups. The results demonstrated that patients with active SLE had significantly lower lymphocyte counts (mean 838.35/μL) compared to inactive patients (mean 1957.65/μL). These findings indicate that a decrease in lymphocyte levels is closely associated with higher disease activity, suggesting that lymphocyte count may serve as a potential indicator of SLE activity. In conclusion, lymphocyte levels can be considered a useful parameter for assessing disease activity in SLE patients undergoing methylprednisolone therapy. This study provides valuable insight for clinical diagnosis and disease activity monitoring. Times New Roman 9 pt and single space. The abstract should contain the background, objectives, methodology, results, and conclusions. The abstract should contain background, objectives, methodology, results, and conclusions and be written in each opening paragraph. The abstract should not contain tables/images without including a citation. The use of abbreviations should be minimum except for units. Objectives and methodology are arranged in the form of past tense, while the results and conclusions in the form of simple present tense.

Downloads

Download data is not yet available.

References

[1] Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB. Systemic lupus erythematosus. Nature Reviews. 2016; 39(2): 1―17

[2] Gao H, Wang Q, Yu X, Liu J, Bai S, et al. Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus : Review. Elsevier. Life Sciences. 2018: 383―7

[3] Feldman CH, Hiraki LT, Liu J. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medical coverage. Arthritis Rheum. 2013; 65: 753―63

[4] Cunha JS, Seibert KG. Systemic lupus erythematosus : A review of the clinical approach to diagnosis and update on current targeted therapies. Rhode Island Medical Journal. 2016: 23―6

[5] Pusat Data dan Informasi Kementerian Kesehatan RI. Situasi lupus di Indonesia. Pusdatin. 2017: 1―7

[6] Tsujimura S, Tanaka Y. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp. Nephrol. 2012; 16: 102―8

[7] Hermosillo LDF, Navedo YR, Nadal AJ, Vila LM. Lymphocyte sensitivity assay as a marker for glucocorticoid resistance in lupus : report of two sisters with systemic lupus erythematosus. Sagepublication. 2014; 23:88: 88―92

[8] Reigosa PJM, Rua-Figueroa I, Lopez-Longo FJ, et al. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. Lupus. 2014; 24: 720―9

[9] Guerrero PEE, Gamez-Nava JI, Munoz-Valle JF, Cardona-Munoz EG, Bonilla-Lara D. Serum levels of p-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus. Spinger. 2017: 1―7

[10] Bazso A, Szappanos A, Patocs A, Poor G, Shoenfeld Y, Kiss E. The Importance of glucocorticoid receptors in systemic lupus erythematosus. A systematic review. Elsevier. 2015; 3: p.1―3

[11] Morris JS, Putterman. Gender Differences in Pathogenesis and Outcome of Lupus and Lupus Nephritis. Clinical and Developmental Immunology. 2012: 1―8

[12] Dhistiarinie PA. Pengaruh Kortikosteroid Pulse Dose Terhadap Sel Limfosit T CD4+, Sel T Regulator, Interleukin-2 dan Nilai MEX-SLEDAI pada Pasien Lupus Eritematosus Sistemik. Tesis Bagian Ilmu Penyakit Dalam FK UNAND. Padang. 2018; 47―48

[13] Tan TC, Fang H, Magder LS, Petri MA. Difference between Male and Female Systemic Lupus Erythematosus in a Multiethnic Population. The Journal of Rheumatology. 2015; 39(4): 759―63

[14] Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male Systemic Lupus Erythematosus: A Review of Sex Disparities in This Disease. Lupus. 2010;19: 119―29

[15] 57.Jakes WR, Bae SC, Lounthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic Review of The Epidemiology of Systemic Lupus Erythematosus in Asia Pacifik Region: Prevalence, Incidence, Clinical Fetaures, and Mortality. American Collage of Rheumatology. 2012;64: 159―68

[16] Carli L, Tani C, Vagnani S, Signorini V, Mosca M. Leukopenia, Lymphopenia and Neutropenia in Systemic Lupus Erythematosus: Prevalence and Clinical Impact. A Systematic Literature Review. Arthritis & Rheumatism. 2015: 1―12

[17] Dias AM, do Couto MC, Duarte CC, Ines LP, Malcata AB. White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE. Ann N Y Acad Sci 2009; 1173: 103―7

[18] Beyan E, Beyan C, Turan M. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology. 2007; 12:257–61

[19] Jeffries M, Hamadeh F, Aberie T, Glenn S, Kamen DL, Kelly JA et al. Haemolytic Anaemia in A Multi-Ethnic Cohort of Lupus Patients: A Clinical and Serological Perspective. Lupus. 2008; 17(8): 739―43

[20] Gormezano NWS, Kern D, Pereira OL, Esteves GCX, Sallum AME, Aikawa NE. Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus at Diagnosis: Differences Between Pediatric and Adult Patients. Lupus. 2016: 1―6

[21] Barbosa VDS, Francescantonio PL, Silva NAD. Leptin and adiponectin in patients with systemic lupus erythematosus: clinical and laboratory correlation. Rev Bras Rheumatology. 2015; 55:140―5.

[22] Gomez-Martin D, Diaz-Zamudio M, Vanoye G, Crispin JC, Alcocer-Varela J. Quantitative and Functional Profiles of CD4+ Lymphocyte Subsets in Systemic Lupus Erythematosus Patients with Lymphopenia. The Journal of Translational Immunology. 2011; 164: 17―25

Downloads

Published

2025-11-01

How to Cite

Lymphocyte Level Profile Between Active and Inactive Systemic Lupus Erythematosus Patients Receiving Methylprednisolon Therapy. (2025). JURNAL FARMASIMED (JFM), 8(1), 153-158. https://doi.org/10.35451/pwmsfc33